Patents by Inventor Don W. Cleveland

Don W. Cleveland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11162096
    Abstract: Disclosed herein are compositions and methods for reducing expression of C9ORF72 antisense transcript in an animal with C9ORF72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C9ORF72 antisense transcript specific inhibitors include antisense compounds.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: November 2, 2021
    Assignees: Ionis Pharmaceuticals, Inc, The Regents of the University of California, Ludwig Institute for Cancer
    Inventors: C. Frank Bennett, Frank Rigo, Don W. Cleveland, Clotilde Lagier-Tourenne, John M. Ravits, Michael W. Baughn
  • Publication number: 20210252039
    Abstract: Provided are compounds, methods, and pharmaceutical compositions for increasing the amount or activity of STMN2 RNA in a cell or animal, and in certain embodiments increasing the amount of STMN2 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include ataxia, neuropathy, synaptic dysfunction, deficits in cognition, and decreased longevity. Such neurodegenerative diseases include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), and dementia with Lewy bodies (DLB).
    Type: Application
    Filed: June 14, 2019
    Publication date: August 19, 2021
    Applicants: Ionis Pharmaceuticals, Inc., Ludwig Institute For Cancer Research
    Inventors: Huynh-Hoa Bui, Don W. Cleveland, Ze'ev Melamed
  • Publication number: 20210169916
    Abstract: Provided are methods for reducing the amount or activity of C9ORF72 RNA, and in certain instances of reducing the amount of C9ORF72 protein, in an animal. Such methods are useful to prevent or ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include anxiety, reduced spatial learning, and memory loss. Such neurodegenerative diseases include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticalbasal degeneration syndrome (CBD), atypical Parkinsonian syndrome, and olivopontocerellar degeneration (OPCD).
    Type: Application
    Filed: July 23, 2020
    Publication date: June 10, 2021
    Applicants: Ionis Pharmaceuticals, Inc., Ludwig Institute for Cancer Research
    Inventors: C. Frank Bennett, Frank Rigo, Don W. Cleveland, Jie Jiang, Qiang Zhu, Clotilde Lagier-Tourene
  • Publication number: 20210139900
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Application
    Filed: October 12, 2020
    Publication date: May 13, 2021
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Publication number: 20210108209
    Abstract: The present invention relates to RNA-based methods for inhibiting the expression of the superoxide dismutase 1 (SOD-1) gene. Recombinant adeno-associated viruses of the invention deliver DNAs encoding RNAs that knock down the expression of SOD-1. The methods have application in the treatment of amyotrophic lateral sclerosis.
    Type: Application
    Filed: August 19, 2020
    Publication date: April 15, 2021
    Inventors: Brian K. Kaspar, Kevin Foust, Don W. Cleveland
  • Patent number: 10837016
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: November 17, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Patent number: 10793861
    Abstract: The present invention relates to RNA-based methods for inhibiting the expression of the superoxide dismutase 1 (SOD-1) gene. Recombinant adeno-associated viruses of the invention deliver DNAs encoding RNAs that knock down the expression of SOD-1. The methods have application in the treatment of amyotrophic lateral sclerosis.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: October 6, 2020
    Assignees: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL, LUDWIG INSTITUTE FOR CANCER RESEARCH
    Inventors: Brian K. Kaspar, Kevin Foust, Don W. Cleveland
  • Publication number: 20200270608
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Application
    Filed: February 26, 2020
    Publication date: August 27, 2020
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Patent number: 10619158
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: April 14, 2020
    Assignee: IONIS Pharmaceuticals, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Publication number: 20190249177
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Application
    Filed: February 8, 2019
    Publication date: August 15, 2019
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Publication number: 20190144868
    Abstract: The present invention relates to RNA-based methods for inhibiting the expression of the superoxide dismutase 1 (SOD-1) gene. Recombinant adeno-associated viruses of the invention deliver DNAs encoding RNAs that knock down the expression of SOD-1. The methods have application in the treatment of amyotrophic lateral sclerosis.
    Type: Application
    Filed: July 20, 2018
    Publication date: May 16, 2019
    Inventors: Brian K. Kaspar, Kevin Foust, Don W. Cleveland
  • Publication number: 20190142856
    Abstract: Provided are methods for reducing the amount or activity of C90RF72 RNA, and in certain instances of reducing the amount of C90RF72 protein, in an animal. Such methods are useful to prevent or ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include anxiety, reduced spatial learning, and memory loss. Such neurodegenerative diseases include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticalbasal degeneration syndrome (CBD), atypical Parkinsonian syndrome, and olivopontocerellar degeneration (OPCD).
    Type: Application
    Filed: April 13, 2017
    Publication date: May 16, 2019
    Applicants: Ionis Pharmaceuticals, Inc., Ludwig Institute for Cancer Research
    Inventors: C. Frank Bennett, Frank Rigo, Don W. Cleveland, Jie Jiang, Qiang Zhu, Clotilde Lagier-Tourene
  • Patent number: 10202603
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: February 12, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Publication number: 20180142240
    Abstract: Disclosed herein are compositions and methods for reducing expression of C9ORF72 antisense transcript in an animal with C9ORF72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C9ORF72 antisense transcript specific inhibitors include antisense compounds.
    Type: Application
    Filed: December 20, 2017
    Publication date: May 24, 2018
    Applicants: Ionis Pharmaceuticals, Inc., The Regents of the University of California, Ludwig Institute for Cancer Research
    Inventors: C. Frank Bennett, Frank Rigo, Don W. Cleveland, Clotilde Lagier-Tourenne, John M. Ravits, Michael W. Baughn
  • Patent number: 9963699
    Abstract: Disclosed herein are methods for reducing expression of C90RF72 mRNA and protein in an animal with C90RF72 specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C90RF72 specific inhibitors include antisense compounds. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration C90RF72 specific inhibitors include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticalbasal degeneration syndrome (CBD), atypical Parkinsonian syndrome, and olivopontocerellar degeneration (OPCD).
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: May 8, 2018
    Assignees: Ionis Pharmaceuticals, Inc., Ludwig Institute for Cancer Research, The Regents of the University of California
    Inventors: C. Frank Bennett, Susan M. Freier, Frank Rigo, Don W. Cleveland, Clotilde Lagier-Tourenne, John M. Ravits, Michael W. Baughn
  • Publication number: 20180087052
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Application
    Filed: May 16, 2017
    Publication date: March 29, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Patent number: 9683236
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: June 20, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Publication number: 20160312217
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Application
    Filed: January 25, 2016
    Publication date: October 27, 2016
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Patent number: 9476051
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: October 25, 2016
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie, Susan M. Freier, Thomas P. Condon, Ravi Jain, Richard Alan Smith, Don W. Cleveland
  • Publication number: 20160272976
    Abstract: The present invention relates to RNA-based methods for inhibiting the expression of the superoxide dismutase 1 (SOD-1) gene. Recombinant adeno-associated viruses of the invention deliver DNAs encoding RNAs that knock down the expression of SOD-1. The methods have application in the treatment of amyotrophic lateral sclerosis.
    Type: Application
    Filed: August 26, 2014
    Publication date: September 22, 2016
    Inventors: Brian K. Kaspar, Kevin Foust, Don W. Cleveland